Floatz logo

DEXAMETHASONE

Breast Diseases

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Breast Diseases cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Incepta Pharmaceuticals Ltd
Phase 3BB
SACUBITRIL VALSARTAN
Silesian Centre for Heart Diseases
Phase 4BB
Capecitabine
University of Southern California
Phase 3B
Letrozole
Fujian Cancer Hospital
Phase 2/3B
TAMOXIFEN
Fujian Cancer Hospital
Phase 2/3B

View all 39 →

Same molecule, other indications

DEXAMETHASONE is also rated in:

chemotherapy-induced toxicityDormant
A
Indicative ·
82 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →